Home › Research › How common it is
Incidence of dementia after age 90 years and association with APOE genotype, race, and sex in the USA: the LifeAfter90 prospective cohort study
Hilary L Colbeth, Maria M Corrada, Dan Mungas, Paola Gilsanz, Kristen M George, Reham Gaied, Claudia H Kawas, Charles DeCarli, et al.. The lancet. Healthy longevity, 2026-08-04
Topic: Risk, prevention and care in population studies
Plain-language summary
In Fine-Gray models, dementia risk was higher in female than in male participants (subdistribution hazard ratio [sHR] 1·89, 95% CI 1·30-2·76) and Black than Asian participants (sHR 1·75, 1·07-2·88), lower in APOE ε2 carriers than in non-carriers (sHR 0·39, 0·17-0·88), and not significantly higher in APOE ε4 carriers than in non-carriers (sHR 1·51, 0·92-2·47). No significant differences were found by education. These findings reinforce the importance of dementia screening and surveillance, even among people with exceptional longevity.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 805 participants. In this cohort of people aged 90 and older, dementia risk was higher in women than men and in Black than Asian participants, and lower in APOE ε2 carriers. Its stated limit: Mean follow-up only 2 years; APOE data available for about half of participants; a single insured health-system population; death as a competing risk was very frequent.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Colbeth, H. L., Corrada, M. M., Mungas, D., Gilsanz, P., George, K. M., Gaied, R., et al. (2026). Incidence of dementia after age 90 years and association with APOE genotype, race, and sex in the USA: the LifeAfter90 prospective cohort study. The lancet. Healthy longevity. https://doi.org/10.1016/j.lanhl.2026.100882
Vancouver
Colbeth HL, Corrada MM, Mungas D, Gilsanz P, George KM, Gaied R, et al. Incidence of dementia after age 90 years and association with APOE genotype, race, and sex in the USA: the LifeAfter90 prospective cohort study. The lancet. Healthy longevity. 2026. doi:10.1016/j.lanhl.2026.100882. PMID: 42551464.
BibTeX
@article{colbeth2026-42551464,
author = {Colbeth, Hilary L and Corrada, Maria M and Mungas, Dan and Gilsanz, Paola and George, Kristen M and Gaied, Reham and Kawas, Claudia H and DeCarli, Charles and others},
title = {{Incidence of dementia after age 90 years and association with APOE genotype, race, and sex in the USA: the LifeAfter90 prospective cohort study}},
journal = {The lancet. Healthy longevity},
year = {2026},
doi = {10.1016/j.lanhl.2026.100882},
pmid = {42551464},
url = {https://doi.org/10.1016/j.lanhl.2026.100882}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In Fine-Gray models, dementia risk was higher in female than in male participants (subdistribution hazard ratio [sHR] 1·89, 95% CI 1·30-2·76) and Black than Asian participants (sHR 1·75, 1·07-2·88), lower in APOE ε2 carriers than in non-carriers (sHR 0·39, 0·17-0·88), and not significantly higher in APOE ε4 carriers than in non-carriers (sHR 1·51, 0·92-2·47).
- No significant differences were found by education.
- These findings reinforce the importance of dementia screening and surveillance, even among people with exceptional longevity.
Why it matters
In this cohort of people aged 90 and older, dementia risk was higher in women than men and in Black than Asian participants, and lower in APOE ε2 carriers. APOE ε4 carriers did not have significantly higher risk in this age group, and the authors stress that screening and monitoring remain important even among people who live exceptionally long.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designcohort
- Participants805
- Effect sizeAge-standardised dementia incidence after 90: 116.82 per 1,000 person-years (95% CI 93.69-139.96); female vs male sHR 1.89 (95% CI 1.30-2.76)
- Evidence strengthModerate
Limitations
Mean follow-up only 2 years; APOE data available for about half of participants; a single insured health-system population; death as a competing risk was very frequent.
How this study scored 55/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 54 of the 98 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The lancet. Healthy longevity) |
| Journal's citation record | 1 / 4 | The Lancet Healthy Longevity: journal h-index 78 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 805 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Rachel A. Whitmer: h-index 63 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of California, Davis: institution h-index 1,257 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42551464) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 54 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 54 of the 98 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
In the news
1 news article on alzhub's news page cites this paper.